On Thursday, our Under the Radar Moversnewsletter suggestedgoing long on small cap clinical-stage biopharmaceutical cancer stock Bellicum Pharmaceuticals (NASDAQ: BLCM):
This entry is probably a little sooner than we’d normally like to get into a budding rebound. But, we’d rather be early than late this time around. As of this week, BLCM shares are above February high, further solidifying the bigger U-shaped (and well-defined) turnaround effort that’s been taking shape for a few weeks now. As you can see from the zoomed-out view, Bellicum Pharmaceuticals is no stranger to big moves, and we like the way this new uptrend got started.
Our Under the Radar Moversnewsletter hasa more detaileddiscussion aboutsmall cap Bellicum Pharmaceuticals technical chart along with a long strategy:
best stock to invest in now: AVEO Pharmaceuticals, Inc.(AVEO)
- [By Lisa Levin]
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) shares shot up 69 percent to $1.23 after the company reported positive CHMP opinion for tivozanib for the treatment of advanced renal cell carcinoma.
best stock to invest in now: Valhi Inc.(VHI)
- [By Lisa Levin]
In trading on Thursday, basic materials shares slipped by 0.61 percent. Meanwhile, top losers in the sector included Valhi, Inc. (NYSE: VHI), down 13 percent, and LSB Industries, Inc. (NYSE: LXU), down 7 percent.
best stock to invest in now: GlobalSCAPE, Inc.(GSB)
- [By Jim Robertson]
On Wednesday, our Under the Radar Moversnewsletter suggested going long on small cap sofware stockGlobalSCAPE, Inc (NYSEMKT: GSB):
As for Globalscape, this one’s a little more straightforward, and obvious. GSB shares pushed up and off of their 200-day moving average line last week, and are making higher highs this week. What you can’t see on the chart is how this has been a pretty reliable pattern for Globalscape for years now. The upper edge of the rising trading range is nearing $6.00, though it would take some time to get there.
best stock to invest in now: PACCAR Inc.(PCAR)
- [By Jim Cramer]
The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Machinery industry and the overall market, PACCAR INC’s return on equity exceeds that of both the industry average and the S&P 500.
- [By JPMorgan]
We are Neutral on PCAR as the company faces the risk of both lower volume and margin pressure from declining demand in its core NA HD truck business in 2016. However, we believe PCAR should command a premium valuation due to its track record of solid execution. In addition, PCAR pays out a normal and a special dividend which, in total, should equal ~50% of net income and currently offers a yield of 4.1% (JPMe total payout of ~$2.12/share) making it potentially attractive to income-oriented investors.
- [By Jim Cramer]
The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Machinery industry. The net income increased by 16.1% when compared to the same quarter one year prior, going from $371.40 million to $431.20 million.
- [By Vikram Nagarkar]
NVIDIA has also recently announced several partnerships lately, like the one with Microsoft,dubbed Olympus, aimed at maximizing GPU performance for data centers. Then there are also other partnerships in the self-driving cars space, like the one with Bosch, and another one with PACCAR (NASDAQ:PCAR), to develop autonomous trucks. Of course, most of these partnerships will most likely take a while before they can translate to any monetary benefits for NVIDIA. What these deals do, though, is reinforce NVIDIA’s grip over this market, which even pushed Intel (NASDAQ:INTC)to acquire Mobileye (NYSE:MBLY), to build a presence in this space. Mobileye is the company that lost business from Tesla Inc (NASDAQ:TSLA)to NVIDIA last year. Putting that aside, more importantly, the price that Intel is paying to acquire Mobileye has indirectly pointed to the fact that NVIDIA may be significantly undervalued.